Editor's note

This article was originally published on 25 March 2008 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

The licensing extension and what it signals

UK/US-based vaccine company Acambis announced that it had extended its licensing agreement for ChimeriVax-JE™ with Sanofi-Pasteur to include marketing rights in India - adding a major and strategically significant market to the earlier licensing arrangement covering other Asia-Pacific territories. VacZine Analytics interpreted the extension as a signal of increased Sanofi confidence in the product's regulatory and commercial prospects, following the emergence of Phase III data that confirmed the vaccine's single-dose immunogenicity and safety profile.

Japanese Encephalitis: the disease burden

Japanese Encephalitis virus (JEV) is a mosquito-borne flavivirus endemic across South and South-East Asia, with approximately 3 billion people living in areas where JEV transmission occurs. An estimated 10,000 deaths and 30,000-50,000 clinical cases are recorded annually, though significant underreporting means the true burden is likely substantially higher. Children under 15 years represent the primary affected population, and survivors of encephalitis frequently suffer permanent neurological sequelae.

At-Risk Population
3bn

Estimated number of people living in areas where Japanese Encephalitis virus is endemic - primarily across South and South-East Asia

"The India licensing extension is more than a commercial transaction - it reflects Sanofi's growing commitment to the South-East Asian vaccines market and to ChimeriVax-JE as its primary vehicle for capturing that opportunity."